NCT00922324

Safety and Tolerability of STP206 in Healthy Adult Subjects

A Single-Center Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Assess the Safety and Tolerability of Single and Multiple Daily Oral Administration of STP206 Live Biotherapeutic in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Leadiant Biosciences, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The study will assess the safety, tolerability and fecal shedding of STP206 when given as a single dose and when given as daily doses for one week.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	STP206 or vehicle control	STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days

Timeline

• Start date: 2010-03-01
• Primary completion: 2010-06-01
• Completion: 2010-11-01
• First posted: 2009-06-17
• Last updated: 2013-05-17

Locations

1 site across 1 country: United States